Compare Hershey Co (HSY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Mesoblast Limited — how do they compare? Hershey Co trades at $162.12 (market cap $32.66B), while Mesoblast Limited trades at $14.28 (market cap $1.75B). The key difference: Hershey Co is far larger — about 18.7× Mesoblast Limited's market cap, and Hershey Co pays a 3.57% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and Mesoblast Limited for 15 Days on average.
| HSY | MESO | |
|---|---|---|
Market Cap | $32.66B | $1.75B |
Volume | 1,578,237 | 239,027 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $20.96 |
52-Week Low | $157.61 | $13.19 |
Typical Hold Time | 135 Days | 15 Days |
Enterprise Value | $37.79B | $1.83B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $161.88, up 0.96% with a bearish technical outlook. The stock shows strong profitability with 12.24% net margin and 32.81% ROE, though Q3 2026 earnings are pending. Recent news highlights brand investments and dividend resumption after a near 2-year freeze. Valuation metrics include P/E of 22.2 and P/S of 2.72, with analyst consensus price target at $204.62 representing 26% upside potential.
HSY presents a mixed investment case with strong fundamentals offset by near-term headwinds. The opportunity lies in consistent dividend growth potential and market leadership, while risks include commodity cost pressures and competitive challenges. Analyst sentiment leans cautious with 66% hold ratings, suggesting patience for earnings catalysts and margin stabilization.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
